Pixium Vision S.A.

One must remember the notion that restoring some vision to those who have lost their sight is possible, has long been thought to be fanciful. However, we are in the Age of Neural Prostheses, Bioelectronics, and BMI. At frontier of neuroscience, interfacing the worlds of eye and the brain – “from Photons to Neurons”. Such is the breadth and depth of knowledge needed to build a world of bionic vision for those with vision loss. This is the mission of Pixium Vision. Two novel life changing Bionic Vision Systems developed, with active implantable prostheses, that are intended to compensate for vision loss and blindness from retinal degeneration, like Dry Age-Related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP), enabling to regain partial central visual perception and lead more independent lives. Advances in neuro-ophthalmology, innovative state of the art biomedical / bioelectronic technologies, smart bio-inspired bio-mimetic algorithms and AI, and miniaturization of micro/nano-electronics, enable minimal invasive retinal surgery, and develop systems that could provide blind people with a form of prosthetic bionic vision. • PRIMA (Subretinal) a miniaturized wireless photovoltaic implant platform initially for Dry-AMD. The company is conducting first-in-human feasibility trials in Europe and the US. • IRIS®II (Epiretinal) its first System for RP, equipped with a bio-inspired camera, an implant with 150 electrodes, designed to be explantable. Formed in Dec 2011, a bioelectronics technology company specialized in neuromodulation to restore a form of prosthetic vision to compensate for blindness. Listed on Euronext Paris stock exchange in June 2014. Collaborates with a global ecosystem of scientific and clinical partners spanning the prestigious Vision research institutions including: Institut de la Vision Paris, Stanford University California, Moorfields Eye Hospital London, and Institute of Ocular Microsurgery (IMO) Barcelona. twitter: @PixiumVision